Patents by Inventor Richard J. Cote

Richard J. Cote has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPUTATIONAL REFOCUSING-ASSISTED DEEP LEARNING
    Publication number: 20220351347
    Abstract: Computational refocusing-assisted deep learning methods, apparatus, and systems are described. In certain pathology examples, a representative image is generated using a machine learning model trained with uniformly focused training images generated by a Fourier ptychographic digital refocusing procedure and abnormalities are automatedly identified and/or enumerated based on the representative image.
    Type: Application
    Filed: February 25, 2022
    Publication date: November 3, 2022
    Inventors: Changhuei Yang, Cheng Shen, Richard J. Cote, Siddarth Rawal
  • Prognostic panel for urinary bladder cancer
    Patent number: 8293880
    Abstract: The present invention relates to methods of prognosing urothelial carcinoma. In one embodiment, the present invention provides a method of prognosing urothelial carcinoma by determining expression levels of JUN, MAP2K6, STAT3 and/or ICAM1. In another embodiment, the present invention provides an single prognostic panel made up of eight gene markers. In another embodiment, the present invention provides a single prognostic panel made up of eleven gene markers.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: October 23, 2012
    Assignee: University of Southern California
    Inventors: Richard J. Cote, Anirban P. Mitra
  • SURFACE MODIFICATION OF NANOSENSOR PLATFORMS TO INCREASE SENSITIVITY AND REPRODUCIBILITY
    Publication number: 20100256344
    Abstract: The present invention relates to various methods of sensitizing and modifying nanosensor platforms. In one embodiment, the present invention provides a method of increasing sensitivity by inhibiting oxidation of one or more 1,4-hydroquinone (HQ) molecules, functionalizing the nanosensor by using one or more diazonium molecules, creating one or more oxidized carbon groups on the nanosensor, and/or depositing one or more metal clusters on the nanosensor.
    Type: Application
    Filed: April 2, 2010
    Publication date: October 7, 2010
    Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Mark E. Thompson, Chongwu Zhou, Richard J. Cote, Fumiaki Ishikawa, Rui Zhang, Marco Curreli
  • PROGNOSTIC PANEL FOR URINARY BLADDER CANCER
    Publication number: 20090246790
    Abstract: The present invention relates to methods of prognosing urothelial carcinoma. In one embodiment, the present invention provides a method of prognosing urothelial carcinoma by determining expression levels of JUN, MAP2K6, STAT3 and/or ICAM1. In another embodiment, the present invention provides an single prognostic panel made up of eight gene markers. In another embodiment, the present invention provides a single prognostic panel made up of eleven gene markers.
    Type: Application
    Filed: March 25, 2009
    Publication date: October 1, 2009
    Applicant: University of Southern California
    Inventors: Richard J. Cote, Anirban P. Mitra
  • Monoclonal antibodies selective for prostate cancer and diagnostic immunoassay for prostate cancer
    Patent number: 5177000
    Abstract: Four monoclonal antibodies are found which selectively identify prostate cancer. These monoclonals are therefore useful in diagnosis and differential diagnosis of prostate cancer.
    Type: Grant
    Filed: August 24, 1990
    Date of Patent: January 5, 1993
    Assignee: Sloan Kettering Institute for Cancer Research
    Inventors: Michel Bazinet, Richard J. Cote, Lloyd J. Old
  • Monoclonal antibodies selective for prostate cancer
    Patent number: 4970299
    Abstract: Four monoclonal antibodies are found which selectively identify prostate cancer. These monoclonals are therefore useful in diagnosis, differential diagnosis and treatment of prostate cancer.
    Type: Grant
    Filed: July 3, 1986
    Date of Patent: November 13, 1990
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Michel Bazinet, Richard J. Cote, Lloyd J. Old
  • Human monoclonal antibodies to cytokeratin
    Patent number: 4727021
    Abstract: Human monoclonal antibodies (HmAbs) capable of reacting with cytokeratin are disclosed. It has been found that HmAbs De8, M54, M307, Hull, C29, Hu22 and Pa24 may be used to detect these cytoskeletal proteins in various cells. By means of these HmAbs the embryological origin of cells may be determined. This information may be used to determine the possible tissue source of metastasized tumors and greatly affects the management of these cancers.
    Type: Grant
    Filed: June 1, 1984
    Date of Patent: February 23, 1988
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Richard J. Cote, Timothy M. Thomson, Alan N. Houghton, Herbert F. Oettgen, Lloyd J. Old
  • Human monoclonal antibodies to cell surface antigens
    Patent number: 4695538
    Abstract: Human monoclonal antibodies (HmAbs) capable of reacting with cell surface antigens and intracellular components are disclosed. It has been found that HmAbs Ev248, Ch-5, Ch-13, Te-39, Hu44, Ge-1, Gr-431, Gr169 and Sp909 may be used to detect these antigens in various cells. By means of these HmAbs malignant cells may be determined. This information may be used to screen metastasized tumors and primary tumors for tissue source and greatly affects the management of these cancers.
    Type: Grant
    Filed: June 1, 1984
    Date of Patent: September 22, 1987
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Richard J. Cote, Timothy M. Thomson, Alan N. Houghton, Herbert F. Oettgen, Lloyd J. Old, Carlos C. Cardo
  • Human monoclonal antibodies from lymphocytes of patients with malignant melanoma
    Patent number: 4693966
    Abstract: Human monoclonal antibodies which specifically bind to antigens found on cell surfaces of renal, lung, and breast cancer cells, intracellular cytoskeletal antigens, nuclear antigens, and cytoplasmic reticular antigens are disclosed. The antibodies are the product of hybridoma cell lines, where the immortal cell line may be, e.g., a human cell line, or a murine cell line.
    Type: Grant
    Filed: March 11, 1983
    Date of Patent: September 15, 1987
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Alan N. Houghton, Hannah Brooks, Richard J. Cote, Herbert F. Oettgen, Lloyd J. Old
  • Human monoclonal antibodies to cancer cells
    Patent number: 4613576
    Abstract: Hybridomas which produce human monoclonal antibodies are disclosed. The hybridomas are formed by fusing lymphocytes from individuals with various cancers to an immortal cell line, such as a myeloma, from, e.g., a human cell line, or a mouse cell line.
    Type: Grant
    Filed: March 9, 1983
    Date of Patent: September 23, 1986
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Richard J. Cote, Donna M. Morrissey, Alan N. Houghton, Edward J. Beattie, Jr., Herbert F. Oettgen, Lloyd J. Old